Divine Aleru, Microbiome Signatures Research Coordinator

This review offers updated guidance on the use of menopausal hormone therapy, highlighting its benefits when started early, particularly for women with low cardiovascular risk. It stresses the importance of individualized care and decision-making when considering HT for managing menopausal symptoms.

This review investigates the stroke risk associated with hormonal therapies in postmenopausal women, comparing oral and transdermal estrogen formulations and highlighting the need for individualized treatment plans based on age and cardiovascular health.

This review explores the thrombosis risks of hormonal therapies, comparing various estrogen formulations and progestins. It emphasizes the need for personalized treatment based on thrombophilic risk factors, highlighting the safer options such as transdermal estrogen and progestin-only therapies.

This study explores estrogen’s effects on thrombosis risk in hormonal contraceptives and HRT, highlighting mechanisms of action, the role of different estrogen doses, and the importance of individualized risk assessments in preventing thromboembolic events.

This study examines estrogen’s dual role in breast cancer, focusing on its effects on estrogen receptor-positive cancers and how different therapies, such as SERMs and aromatase inhibitors, mitigate risks while highlighting estrogen metabolism’s role in cancer risk.

The study emphasizes the risks and benefits of menopausal hormone therapy in managing vasomotor symptoms, osteoporosis, and cardiovascular health. It highlights the importance of timing, formulation, and route of administration in optimizing therapy for individual patients.

This review emphasizes the benefits and risks of MHT in managing menopause symptoms, including the prevention of long-term conditions. It advocates for individualized treatment plans, especially focusing on the timing of initiation.

This guideline on menopausal symptom treatment prioritizes early initiation of hormone therapy, safe routes like transdermal estradiol, and vaginal care for genitourinary symptoms. It promotes a tailored approach considering cardiovascular and breast cancer risks.

The review defines menopause vasomotor symptoms treatment and microbiome relevance, favors timely hormone therapy and transdermal routes, details effective nonhormone options, and highlights neurokinin antagonists for fast relief while separating vasomotor and genitourinary care for microbiome-aware practice.

This review sets a simple plan for menopausal hormone therapy first-line management, favors transdermal routes when risk exists, and backs local therapy for genitourinary symptoms with clear links to vaginal ecosystem health.

The review shows that menopausal hormone therapy osteoporosis prevention lowers fractures when started near menopause, favors transdermal routes for safety, and maps RANKL–OPG and cytokine shifts with clear microbiome relevance despite no direct microbiota data.

The guideline links menopausal hormone therapy guidelines and vaginal microbiome care to safer symptom control, better GSM outcomes, and lower UTI risk through local estrogen, with timing and route choices that manage vascular and endometrial risk.

The review defines progesterone endometrial tumor suppressor mechanisms, links receptor biology to therapy response, and outlines immune and barrier changes with clear microbiome relevance despite no direct taxa reporting.

This review links menopausal hormone therapy and vaginal microbiome care to safer symptom relief, bleeding control, and prevention. It favors transdermal estradiol and physiologic progestogens, and it highlights estriol plus lactobacilli for urogenital symptoms with minimal systemic exposure.

Hormone Replacement Therapy (HRT) is one of the most effective treatments for women experiencing the symptoms of menopause, particularly vasomotor symptoms such as hot flashes and night sweats. But its benefits go beyond just symptom management. HRT can also play a key role in improving vaginal health by alleviating dryness and discomfort, which are common complaints among women in menopause. Additionally, it helps prevent bone loss, significantly reducing the risk of osteoporosis and fractures, which are more common after menopause. Despite its many benefits, HRT is not one-size-fits-all; it’s essential to tailor treatment based on individual health profiles, taking into account the risks like breast cancer, blood clots, and heart disease that come with prolonged use.

This study demonstrates the potent anticancer effects of a tumor-resident bacterial consortium in both immunocompetent and immunocompromised mice. The consortium induces tumor remission through selective thrombosis, necrosis, and biofilm formation, offering a promising drug-free strategy for cancer therapy with potential applications in treating solid tumors.

This review explores the role of microbiome-derived metabolites in inflammation-related cancer prevention and treatment, highlighting their dual effects in modulating inflammation and immune responses. It discusses key metabolites such as SCFAs, polyamines, and bile acids, along with emerging therapies and the challenges in translating these findings into clinical practice.

This review explores the dual role of gut microbial metabolites in cancer, focusing on their anticancer and pro-carcinogenic effects. It emphasizes the potential of SCFAs, bacteriocins, and dietary modifications in preventing and treating cancer, with a focus on colorectal cancer and other common malignancies.

The review examines the therapeutic potential of FMT and next-generation microbiome therapies in treating metabolic disorders. It highlights the promising role of FMT in restoring microbial balance and improving conditions like obesity and type 2 diabetes, though challenges remain in optimizing treatment protocols.

This review examines the immunomodulatory effects of probiotics, detailing how they enhance immune functions through interactions with immune cells in the gut. Probiotics help regulate cytokine release, boost IgA production, and support gut health, offering potential therapeutic benefits for immune disorders.

The review discusses the impact of gut microbiota on cancer therapy outcomes, focusing on chemotherapy and immunotherapy. It highlights how microbiota influences drug effectiveness and immune responses, emphasizing the potential of microbiota modulation for personalized treatment approaches.

This review emphasizes how gut microbiota influences cancer chemotherapy efficacy and toxicity. It discusses microbial species, metabolites, and strategies to optimize chemotherapy response, suggesting that microbiota modulation could improve treatment outcomes.

This review explores the dual role of the intratumoral microbiome in cancer, highlighting its impact on immune modulation and its potential as a target for innovative therapeutic strategies, including enhancing immunotherapy efficacy.

This review explores bacteria-based immunotherapy for cancer, highlighting how bacteria and their components modulate immune responses to enhance tumor targeting and therapy outcomes. It also discusses the potential for combining bacteria with traditional therapies like chemotherapy and immune checkpoint inhibitors.

This review explores the complex role of intratumoral microbiota in cancer, emphasizing their influence on immune responses and the potential for microbiome-based therapies in cancer immunotherapy. It discusses how specific microbes affect tumor progression and therapy resistance, offering insights into new treatment strategies.

This review explores the complex role of microbial metabolites in cancer, focusing on their impact on tumor initiation, progression, metastasis, and therapy response. It highlights how microbial products influence the tumor microenvironment and immune modulation, suggesting new avenues for cancer therapy.

This review explores the role of metabolism in cancer, highlighting how tumors adapt their metabolism to survive in the tumor microenvironment (TME) and how systemic metabolism influences treatment. It discusses metabolic reprogramming, immune competition, and the potential for targeted therapies to improve cancer treatment outcomes.

This review explores the complex relationship between inflammation and cancer, examining how chronic inflammation drives tumor initiation, progression, and metastasis. It highlights potential therapeutic strategies targeting inflammatory pathways to improve cancer treatment outcomes.

This review examines the role of intratumoral microbiota in cancer progression, immune modulation, and therapy resistance. It highlights microbial species involved in tumor growth and discusses the potential of microbiome-based treatments to improve cancer therapies.

This review investigates the spatial heterogeneity of intratumoral microbiota and its impact on cancer immunotherapy resistance. It highlights how microbial distribution within tumors influences immune responses and treatment efficacy, suggesting new strategies to overcome resistance and improve cancer therapy outcomes.

The review highlights the role of intratumoral microbiota in cancer initiation, progression, and therapy. It discusses the dual effects of these microbiota on immune responses, emphasizing their potential as diagnostic biomarkers and therapeutic targets in cancer treatment.

What was studied?This review article explores the role of intratumoral microbiota in cancer initiation, progression, and therapeutic responses. It highlights the complex interactions between microbial communities and the tumor microenvironment (TME) in various cancers, including colorectal, breast, pancreatic, and lung cancers. The review investigates how the presence of specific microbes within tumor tissues influences carcinogenesis, […]

This review explores the role of fungi in cancer progression, highlighting their impact on tumor development and immune responses. It emphasizes the potential for mycobiome-based cancer diagnostics and therapies, though challenges remain in understanding the exact mechanisms at play.

This review examines the role of intratumoral microbiota in colorectal cancer. It highlights how specific microbes influence tumor progression, immune responses, and therapy resistance, suggesting microbiota manipulation as a novel therapeutic approach.

This review explores how the oral microbiota influences cancer pathogenesis, highlighting its role in immune modulation, inflammation, and tumor progression. It emphasizes the potential of oral microbiota manipulation in improving cancer diagnosis and treatment outcomes.

This review explores how intratumoral microbiota influence cancer initiation, progression, and therapy. It highlights their roles in immune modulation, tumor growth, and therapeutic resistance, suggesting microbiome manipulation as a potential therapeutic strategy.

This review discusses how intratumoral microbiota influence cancer progression and therapy. It explores their roles in immune modulation, inflammation, and treatment resistance, and suggests microbiota manipulation as a potential therapeutic strategy for enhancing cancer treatment outcomes.

This review explores the role of intratumoral microbiota in cancer progression and immunity. It discusses how microbiota influence tumor behavior and therapy outcomes, suggesting potential therapeutic strategies and biomarkers for cancer treatment.

This review explores the role of intratumoral microbiota in cancer onset and progression, emphasizing their potential therapeutic applications in improving cancer treatment outcomes and offering new insights into cancer therapy.

With the growing understanding of the intratumoral microbiota’s influence on cancer progression, the next frontier in cancer therapy is microbiota-targeted interventions. By introducing beneficial microbes or altering existing microbial populations within tumors, therapies can be designed to modulate the immune system, promote tumor suppression, and improve drug efficacy. However, challenges remain in deciphering the complex relationships between microbes, tumor cells, and the immune system, necessitating more refined research methods and standardized approaches to translate these discoveries into clinical practice.

This review elucidates the hormonal and physiological mechanisms underpinning female puberty, detailing HPG and HPA axis activation, pubertal milestones, and regulatory factors, and discusses implications for clinical assessment and future microbiome research integration.

A comprehensive review of the hormonal regulation of puberty, diagnostic markers for distinguishing healthy from disordered puberty, and the implications for clinical practice, with emphasis on the endocrine framework relevant to future microbiome research.

This study identifies significant differences in age of menarche between rural and urban Nigerian girls, highlighting the influence of socioeconomic status and residence. Findings have implications for understanding pubertal timing and its potential links to the microbiome and long-term health risks.

A comprehensive review of evidence on the determinants and health implications of ages at menarche and menopause, highlighting their complex, independent origins and the influence of life-course genetic, environmental, and socioeconomic factors. No consistent direct association was found between the timing of menarche and menopause.

This commentary reviews the global neglect of menstrual health education at menarche, highlighting psychosocial and health consequences for girls. It advocates for standardized, early education and support to empower girls and improve reproductive health, with implications for microbiome-related outcomes.

This study explores the factors influencing age at menarche, menstrual knowledge, and hygiene practices among schoolgirls in Sharjah, UAE. It highlights how socioeconomic factors, education, and hygiene practices impact menstrual health outcomes.

Menarche marks the first occurrence of menstruation, signaling a pivotal moment in a young girl’s transition to womanhood. Understanding this process helps to shed light on the hormonal, physical, and emotional changes that accompany puberty. Explore the importance of menarche, factors that influence its timing, and how it shapes women’s health throughout their lives.

This review explores the link between endometriosis and ovarian cancer, focusing on genetic mutations like ARID1A, oxidative stress, and estrogen receptor loss, which contribute to the development of malignancy, particularly in the endometrioid and clear-cell subtypes.

This review explores the molecular pathogenesis of endometriosis-associated ovarian cancer, highlighting key genetic mutations, hormonal imbalances, and microRNA dysregulation that contribute to the disease. It discusses the potential for personalized treatment strategies based on molecular signatures to improve outcomes in affected patients.

This study examines the association between metformin use and survival outcomes in ovarian cancer patients. A significant survival benefit was found in diabetic patients, suggesting metformin may improve ovarian cancer prognosis, although further research is needed for non-diabetic patients.

This review explores the potential of repurposing non-oncological drugs for cancer therapy, highlighting their efficacy in preclinical studies and their mechanisms of action. It emphasizes the benefits of using established drugs to overcome cancer treatment challenges, particularly in overcoming drug resistance and reducing costs.

The review explores the potential of repurposing non-oncological drugs for ovarian cancer treatment, highlighting their ability to improve chemotherapy effectiveness and reduce treatment costs, with promising findings from preclinical studies and clinical trials.

What was studied?The study explores drug repositioning as a transformative strategy for ovarian cancer (OC) treatment, highlighting the potential of repurposing existing drugs for more effective, accelerated, and cost-efficient therapies. The review focuses on in vitro experiments with various cancer cell lines and preclinical in vivo models to evaluate the efficacy of repurposed drugs, including […]

This review explores the role of targeted therapies in ovarian cancer treatment, focusing on the potential of angiogenesis inhibitors, PARP inhibitors, and folate receptor alpha inhibitors. While promising, further clinical trials and personalized approaches are necessary to enhance survival and treatment outcomes.

This review discusses the role of nutritional interventions in improving the nutritional status and clinical outcomes of women with ovarian cancer during treatment. It highlights the importance of personalized nutrition care and the need for more research to establish effective intervention strategies.

his systematic review highlights the role of metabolomics in ovarian cancer management, identifying key metabolic alterations in lipids and amino acids that could improve diagnosis, prognosis, and treatment strategies. Further validation is needed for clinical application.

This study profiles metabolic dysregulation in ovarian cancer, identifying key metabolites and pathways altered in OC tissues and biofluids. N1,N12-diacetylspermine emerges as a potential biomarker.

Mendelian randomization identified causal links between 9 metabolites and ovarian cancer risk. Some metabolites promote, others protect against OC. These findings suggest potential biomarkers for diagnosis and treatment but require clinical validation.

A two-sample MR of 486 metabolites reports suggestive causal links across OC and histotypes, maps caffeine/arginine/TCA and alpha-linolenic pathways, and surfaces microbially influenced xenobiotics as potential biomarkers; findings require replication before translation.

This review explores how heavy metals, including cadmium, lead, and mercury, contribute to the development of female cancers by mimicking estrogen, inducing oxidative stress, and causing DNA damage. These findings highlight the need for further research to understand the molecular mechanisms involved and develop effective prevention strategies.

This study investigates how sub-chronic exposure to lead, cadmium, and cobalt induces multidrug resistance in ovarian cancer cells, highlighting the role of drug efflux transporters and reduced apoptosis in treatment resistance. These findings underscore the importance of environmental metal exposure in cancer therapy effectiveness.

The study examines the association between urinary concentrations of heavy metals (arsenic, cadmium, mercury, lead) and survival in patients with advanced high-grade serous ovarian cancer. High levels of these metals correlate with worse outcomes, particularly lead, which significantly contributes to survival prognosis.

This study explores the role of lead and cadmium in gynecological malignancies, focusing on their ability to mimic estrogen and induce oxidative stress, contributing to cancer development. It highlights their potential as biomarkers for early detection and treatment.

This study explores how the concentration of heavy metals, particularly zinc and copper, in the blood of ovarian cancer patients correlates with their recurrence-free survival. It highlights the potential of these metals as biomarkers for prognosis and suggests environmental factors play a role in cancer outcomes.

This review explores the role of the microbiome in ovarian cancer, focusing on microbial dysbiosis and bacterial metabolites that influence inflammation and carcinogenesis. It highlights the potential of microbiome-based therapies, such as probiotics and antibiotics, to improve treatment outcomes and provide new diagnostic tools.

This review explores the ovarian cancer-associated microbiome’s role in shaping the inflammatory microenvironment of tumors. It discusses how microbial dysbiosis and its metabolites contribute to cancer progression, immune suppression, and therapeutic resistance, suggesting microbiome modulation as a potential therapeutic strategy.

This review explores how the microbiome influences ovarian cancer development, progression, and treatment response. It emphasizes microbial dysbiosis as a factor in carcinogenesis and offers insights into therapeutic opportunities like probiotics and fecal microbiota transplantation to improve treatment outcomes.

This review examines how the aging gut microbiome affects ovarian cancer progression. It highlights microbial dysbiosis as a common feature in both aging and cancer, with implications for novel therapeutic strategies like probiotics and fecal microbiota transplantation to improve treatment outcomes.

This review highlights the role of vaginal microbiota in ovarian cancer carcinogenesis, progression, and treatment. It discusses microbial dysbiosis and potential therapeutic interventions like probiotics and vaginal microbiota transplantation, offering promising avenues for improving cancer treatment.

This review highlights the significant role of the female reproductive tract microbiome in the development of gynecological cancers, focusing on microbial dysbiosis, estrogen regulation, and potential therapeutic strategies.

This review examines the role of the microbiome in gynecologic cancer development and treatment, emphasizing its potential for early diagnosis and therapeutic modulation. The microbiome’s influence on chemotherapy and immunotherapy responses offers new avenues for cancer management.

This review explores the role of the microbiome in ovarian cancer, emphasizing its potential for early diagnosis and treatment. The use of microbiome-based biomarkers and therapies like fecal and vaginal microbiome transplantation offers promising new avenues for cancer care.

This study investigates the effects of ketogenic and high-fat diets on gut microbial composition and ovarian cancer progression in mice. It shows that high-fat diets increase tumor growth and disrupt microbial diversity, highlighting the potential role of diet in cancer therapy and prevention.

This review examines the relationship between diet and ovarian cancer risk, finding that animal fats and dairy are linked to higher risk, while vegetables and bioactive compounds may offer protective benefits, although results are inconsistent across studies.

This case-control study highlights the significant role of diet in ovarian cancer risk, with high vegetable and fruit intake reducing risk, while animal fats and salted vegetables increase it. Fried and smoked foods also contribute to a higher risk.

This review underscores the importance of diet and physical activity in modulating the gut microbiome of cancer patients. Diets like fiber-rich and Mediterranean diets show promise in improving cancer treatment outcomes. Exercise also enhances microbial diversity and immune function, potentially improving patient quality of life.

Probiotics were shown to significantly reduce cancer cell proliferation, promote apoptosis, and inhibit migration in breast and ovarian cancer cells, suggesting their potential as adjunctive cancer therapies.

This review maps advances in ovarian cancer management, from surgery and chemotherapy to targeted and emerging therapies, and highlights a need to integrate microbiome insights.

This review analyzes the global epidemiology and risk factors of ovarian cancer, emphasizing the role of genetic predispositions, reproductive factors, and lifestyle choices. It highlights the disparities in incidence and mortality rates across regions and calls for better prevention and early detection strategies.

This review discusses ovarian cancer diagnosis, molecular characteristics, and treatment strategies, emphasizing the role of targeted therapies like PARP inhibitors and immunotherapy, with a focus on personalized treatment approaches based on genetic and molecular tumor profiles.

This review covers the epidemiology, genetics, and molecular mechanisms of ovarian cancer, focusing on the role of estrogen receptors and genetic mutations such as BRCA1/2. It emphasizes the importance of genetic testing and the potential of targeted therapies, including PARP inhibitors, for improving patient outcomes.

This review discusses liquid biopsy techniques for early ovarian cancer detection, focusing on circulating tumor cells, cell-free DNA, and extracellular vesicles. It highlights their potential to improve sensitivity, specificity, and prognosis prediction, providing a promising avenue for non-invasive cancer screening.

This review explores the molecular mechanisms of ovarian cancer metastasis, focusing on the role of stromal cells and the metastatic routes—passive dissemination and hematogenous spread—while discussing therapeutic implications for targeting both cancer cells and the tumor microenvironment.

Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its “silent” progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.

This study explored the role of hormone replacement therapy (HRT) in reversing gut microbiome and serum metabolome alterations in women with premature ovarian insufficiency (POI), identifying potential therapeutic targets for microbiome-based interventions.

This review explores butyrate’s role as a modulator in gynecological diseases, including PCOS, endometriosis, and cancer, highlighting its potential as a therapeutic agent through immune modulation, inflammation reduction, and cancer inhibition.

This paper explores how gut microbiota dysbiosis contributes to premature ovarian failure (POF) and highlights potential therapeutic interventions targeting GM for better management of POF.

This review explores how gut microbiota modulation influences ovarian aging and presents potential therapies like fecal microbiota transplantation and probiotics to prevent or alleviate ovarian aging, offering new strategies for preserving reproductive health.

This review examines the relationship between gut microbiota and ovarian aging, highlighting microbial dysbiosis as a key factor in ovarian function decline. It explores microbiota-based therapies like FMT to delay ovarian aging and discusses the role of dietary and pharmacological interventions.

This study demonstrates the effectiveness of ultrasound-guided hUC-MSC exosome injection in restoring ovarian function and fertility in POI rat models, offering a new therapeutic approach for women with POI.

This study demonstrates that metformin protects against chemotherapy-induced ovarian failure by reducing inflammation, oxidative stress, and senescence in granulosa cells via the AMPK/PPAR-γ/SIRT1 pathway.

The review discusses the therapeutic use of hormone replacement therapy (HRT) for managing POI and early menopause, highlighting its benefits in preventing complications like osteoporosis, cardiovascular disease, and depression.

This study identifies 27 metabolites linked to primary ovarian insufficiency (POI), revealing novel metabolic pathways and offering insights into POI biomarkers and therapeutic targets.

This study identifies 33 serum metabolites, including N-acetylalanine, linked to an increased risk of primary ovarian insufficiency (POI), offering new insights into the disease’s genetic and metabolic causes.

This study identifies metabolic disruptions in POI, including altered amino acid and lipid metabolism. Key metabolites such as acetoacetate and HDCA were found to be potential biomarkers, shedding light on the oxidative stress and mitochondrial dysfunction involved in POI.

This study examines the metabolic profile of women with premature ovarian insufficiency, finding significant changes in lipid and glucose metabolism. The results underscore the importance of early metabolic screening and management to reduce cardiovascular and metabolic risks associated with POI.

This study investigates the metabolic differences in women with premature ovarian insufficiency (POI), highlighting increased waist circumference, cholesterol, and glucose levels. It underscores the importance of early metabolic screening and management to address the elevated cardiovascular risk associated with POI.

This study identifies key metabolites altered in premature ovarian insufficiency (POI), including arachidonoyl amide and 18-HETE, which could serve as diagnostic biomarkers. The findings reveal insights into the metabolic disturbances of POI, offering potential therapeutic directions.

This study explores the potential link between serum heavy metal levels and premature ovarian insufficiency. The higher levels of metals like lead and mercury in women with POI suggest environmental toxins may contribute to ovarian dysfunction, though the findings were not statistically significant.

This review highlights the impact of heavy metal-induced oxidative stress on ovarian function, contributing to premature ovarian insufficiency. It discusses the mechanisms by which metals like copper, arsenic, and cadmium induce ROS, leading to ovarian damage, and the potential therapeutic role of antioxidants.